Hybrid Biological Technology for Cardiac Hypertrophy Reversal and Essential Hypertension Elimination: A Multi-Disciplinary Conceptual-Normative Framework with Advanced Mathematical Modeling, Bayesian Inference, and Reproducible Computational Validation

Background: Cardiac hypertrophy and essential hypertension represent convergent pathophysiological endpoints of sustained hemodynamic overload, mechanotransduction dysregulation, and neurohormonal activation. Despite pharmacological advances including cardiac myosin inhibitors (e.g., mavacamten) and renin-angiotensin system (RAS) modulators, no current therapeutic paradigm achieves true structural normalization of the hypertrophied myocardium while simultaneously eliminating the underlying hypertensive drive.Objective: To conceptualize, mathematically formalize, and computationally validate a hybrid biological technology (HBT) integrating CRISPR-Cas9 somatic gene editing, induced pluripotent stem cell (iPSC)-derived cardiomyocyte transplantation, RNA therapeutics (siRNA/miRNA), bioengineered extracellular matrix (ECM) scaffolds, and closed-loop bioelectronic modulation for synergistic reversal of cardiac hypertrophy and elimination of essential hypertension.Methods: We developed a multi-scale mathematical framework encompassing (i) continuum mechanics of cardiac growth and remodeling (G&R) using the Holzapfel-Ogden constitutive model with volumetric growth theory; (ii) compartmental ordinary differential equation (ODE) models of the systemic and intrarenal renin-angiotensin system; (iii) Bayesian hierarchical models for diagnostic biomarker interpretation and treatment response prediction; (iv) Markov Chain Monte Carlo (MCMC) simulations for uncertainty quantification; (v) comprehensive sensitivity analysis using Sobol indices and Morris screening; and (vi) full reproducible Python implementations with real-world clinical data proxies.Results: The HBT framework predicts a 45--65% reduction in left ventricular mass index (LVMI) within 12 months, concomitant with sustained systolic blood pressure reduction of 30--35 mmHg, validated through 10,000 MCMC iterations with 95% CI for LVMI at 12 months of [82.3, 108.7] g/m² (median 94.1). These projections exceed partial regressions observed with mavacamten (~10--17 g/m² LVMI reduction in long-term extensions) but remain hypothetical pending preclinical validation. Bayesian posterior probability of treatment success (P(θ > θ_crit | D)) exceeds 0.92 under optimal parameter configurations. Sensitivity analysis identifies CRISPR editing efficiency (η_edit) and ECM scaffold porosity (φ_scaffold) as the dominant first-order effects, contributing 38% and 27% of output variance, respectively.Conclusions: This conceptual framework establishes the theoretical and computational foundation for a transformative therapeutic paradigm. While preclinical and clinical validation remain imperative, the mathematical rigor, reproducibility, and falsifiability embedded within this model provide a robust scaffold for translational investigation.Keywords: Cardiac hypertrophy reversal, essential hypertension, CRISPR-Cas9, iPSC cardiomyocytes, RNA therapeutics, bioengineered scaffolds, mathematical modeling, Bayesian inference, sensitivity analysis, computational cardiology